出血性疾患治療市場：疾患タイプ、薬剤クラス別、流通チャネル別-2025～2030年の世界予測

出血性疾患治療市場は、2023年に135億6,000万米ドルと評価され、2024年には148億米ドルに達すると予測され、CAGR 9.29％で成長し、2030年には252億5,000万米ドルに達すると予測されています。

出血性疾患治療市場には、体内凝固機構の欠陥や機能不全による異常出血や過剰出血を特徴とする病態を管理することを目的とした幅広い製品とサービスが含まれます。血友病、von Willebrand病、その他の稀な出血性疾患などの症状によって必要とされるこのセグメントの用途は、病院、専門クリニック、在宅医療にまたがり、最終用途は、効果的で便利な治療オプションを求める医療機関や個人によるものです。市場洞察によれば、認知度の向上、遺伝子組換え技術の進歩、出血リスクを事前に軽減する予防的治療の採用急増が、市場の堅調な成長を牽引しています。さらに、政府の支援と有利な償還ポリシーが市場拡大をさらに後押ししています。最近のビジネス機会は、遺伝子治療と非代替療法の統合によってもたらされ、製薬業界におけるパートナーシップとイノベーションの余地を提供しています。しかし、治療費の高騰、規制要件の厳格化、新興国地域での治療アクセスの制限といった課題も残っており、市場拡大の妨げとなる可能性があります。技術革新の面では、半減期が延長された凝固因子、遺伝子編集技術、個人の遺伝子プロファイルに合わせた治療を行う個別化医療アプローチといったセグメントが潜在的な成長の道を示しています。企業は、使いやすい送達システムやモニタリング・管理用のモバイルアプリケーションの開発など、利便性とコンプライアンスを向上させる技術に注力することで利益を得ることができると考えられます。出血性疾患治療市場は、急速な進歩と競争の激しい状況を特徴としており、継続的な研究開発投資が必要です。要するに、業界の利害関係者は俊敏性を維持し、研究開発の翼を強化し、戦略的提携関係を構築して成長機会を獲得する一方、市場シェアを効率的に最大化するために既存の障壁に対処する必要があります。

市場力学：急速に進化する出血性疾患治療市場の主要市場洞察を公開

出血性疾患治療市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネス機会の獲得に備えることができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 肝障害と貧血の有病率の増加
  • 政府による医療支出の増加
  • 各国における医療へのアクセシビリティの大幅な向上
• 市場抑制要因
  • 熟練した専門家と訓練された専門知識の不足
• 市場機会
  • 出血性疾患に対する意識の高まり
  • 感染リスクの低下と研究開発への高額投資による需要の増加
• 市場課題
  • 出血性疾患治療の薬価の高さ

ポーターのファイブフォース：出血性疾患治療市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、出血性疾患治療市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォースフレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：出血性疾患治療市場における外部からの影響の把握

外部マクロ環境要因は、出血性疾患治療市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：出血性疾患治療市場における競合情勢の把握

出血性疾患治療市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的な意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス出血性疾患治療市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、出血性疾患治療市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨：出血性疾患治療市場における成功への道筋を描く

出血性疾患治療市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネス機会を活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目セグメントを網羅した市場の包括的な分析を提供しています。

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存セグメントにおける拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています。

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、地域はどこか？

3.市場を形成する主要技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 肝疾患と貧血の罹患率の増加
    • 政府による医療費支出の増加
    • 経済における医療へのアクセスが大幅に向上
  • 抑制要因
    • 熟練した専門家と訓練された専門知識の不足
  • 機会
    • 出血性疾患に関する意識の高まり
    • 感染リスクの低下と研究開発への多額の投資による需要の増加
  • 課題
    • 出血性疾患治療の薬代が高い
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 出血性疾患治療市場：疾患タイプ別

• イントロダクション
• 血友病A
• 血友病B
• フォン・ヴィレブランド病

第7章 出血性疾患治療市場：薬剤クラス別

• イントロダクション
• 抗ブリン溶解薬
• デスモプレシン
• フィブリンシーラント
• 血漿由来凝固因子濃縮物
• 組換え凝固因子濃縮物

第8章 出血性疾患治療市場：流通チャネル別

• イントロダクション
• 調剤薬局
• 病院薬局
• 小売薬局

第9章 南北アメリカの出血性疾患治療市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋の出血性疾患治療市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの出血性疾患治療市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Alnylam Pharmaceuticals Inc.
• Amgen Inc.
• Baxter International Inc.
• Bayer AG
• Biogen Inc.
• Bristol-Myers Squibb Company
• CSL Behring
• Emergent BioSolutions Inc.
• Grifols International, S.A.
• Kedrion S.p.A.
• Novo Nordisk A/S
• Octapharma AG
• Pfizer Inc.
• Sanofi S.A.
• Xenetic Biosciences, Inc.

LIST OF FIGURES

• FIGURE 1. BLEEDING DISORDERS TREATMENT MARKET RESEARCH PROCESS
• FIGURE 2. BLEEDING DISORDERS TREATMENT MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. BLEEDING DISORDERS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. BLEEDING DISORDERS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. BLEEDING DISORDERS TREATMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. BLEEDING DISORDERS TREATMENT MARKET DYNAMICS
• TABLE 7. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY HEMOPHILIA A, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY HEMOPHILIA B, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY VON WILLEBRAND DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ANTIBRINOLYTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DESMOPRESSIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY FIBRIN SEALANT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PLASMA DERIVED COAGULATION FACTOR CONCENTRATES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COMPOUNDING PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 29. BRAZIL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 30. BRAZIL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 31. CANADA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 32. CANADA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 33. CANADA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 35. MEXICO BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 36. MEXICO BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 40. UNITED STATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 44. ASIA-PACIFIC BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 46. AUSTRALIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 47. AUSTRALIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 48. CHINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 49. CHINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 50. CHINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 51. INDIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 52. INDIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 53. INDIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 55. INDONESIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 56. INDONESIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 58. JAPAN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 59. JAPAN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 61. MALAYSIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 62. MALAYSIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 64. PHILIPPINES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 65. PHILIPPINES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 67. SINGAPORE BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 68. SINGAPORE BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 70. SOUTH KOREA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 71. SOUTH KOREA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 73. TAIWAN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 74. TAIWAN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 76. THAILAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 77. THAILAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 79. VIETNAM BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 80. VIETNAM BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 84. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 86. DENMARK BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 87. DENMARK BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 89. EGYPT BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 90. EGYPT BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 92. FINLAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 93. FINLAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 95. FRANCE BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 96. FRANCE BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 98. GERMANY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 99. GERMANY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 101. ISRAEL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 102. ISRAEL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 103. ITALY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 104. ITALY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 105. ITALY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 107. NETHERLANDS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 108. NETHERLANDS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 110. NIGERIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 111. NIGERIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 113. NORWAY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 114. NORWAY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 115. POLAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 116. POLAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 117. POLAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 118. QATAR BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 119. QATAR BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 120. QATAR BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 122. RUSSIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 123. RUSSIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 125. SAUDI ARABIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 126. SAUDI ARABIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 131. SPAIN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 132. SPAIN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 134. SWEDEN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 135. SWEDEN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 137. SWITZERLAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 138. SWITZERLAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 140. TURKEY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 141. TURKEY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 143. UNITED ARAB EMIRATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 144. UNITED ARAB EMIRATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 146. UNITED KINGDOM BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 147. UNITED KINGDOM BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 148. BLEEDING DISORDERS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 149. BLEEDING DISORDERS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

The Bleeding Disorders Treatment Market was valued at USD 13.56 billion in 2023, expected to reach USD 14.80 billion in 2024, and is projected to grow at a CAGR of 9.29%, to USD 25.25 billion by 2030.

The market for bleeding disorders treatment encompasses a wide range of products and services aimed at managing conditions characterized by abnormal or excessive bleeding due to deficiencies or dysfunctions in the body's clotting mechanism. Necessitated by conditions such as hemophilia, von Willebrand disease, and other rare bleeding disorders, the field's application spans across hospitals, specialty clinics, and home-care settings, with significant end-use coming from healthcare institutions and individuals seeking effective and convenient treatment options. The market insights reveal robust growth driven by increased awareness, advancements in recombinant technology, and a surge in prophylactic treatment adoption, which mitigates bleeding risks before they occur. Moreover, government support and favorable reimbursement policies further propel market expansion. Recent opportunities are presented by the integration of gene therapies and non-replacement therapies, offering room for partnerships and innovation within pharmaceutical circles. However, the market still faces challenges such as high treatment costs, stringent regulatory requirements, and limited access to treatment in developing regions, which could hinder expansion. In terms of innovation, areas such as extended half-life clotting factors, gene editing technologies, and personalized medicine approaches to tailor treatments to individual genetic profiles represent potential growth avenues. Businesses could benefit by focusing on technology that improves convenience and compliance, such as developing user-friendly delivery systems and mobile applications for monitoring and management. The bleeding disorders treatment market is characterized by rapid advancements and a competitive landscape, necessitating continuous research and development investments. In essence, industry stakeholders need to maintain agility, bolster their R&D wings, and develop strategic alliances to capture growth opportunities, while addressing prevailing barriers to maximize their market share efficiently.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Bleeding Disorders Treatment Market

The Bleeding Disorders Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increase in the prevalence of liver disorders and anemia
  • Rising healthcare expenditure by the government
  • Considerable increase in healthcare accessibility in economies
• Market Restraints
  • Lack of skilled professionals and trained expertise
• Market Opportunities
  • Rising awareness regarding bleeding disorders
  • Rise in demand due to lower infection risks and high investments in research and development
• Market Challenges
  • High cost of medications of bleeding disorders treatment

Porter's Five Forces: A Strategic Tool for Navigating the Bleeding Disorders Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Bleeding Disorders Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Bleeding Disorders Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Bleeding Disorders Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Bleeding Disorders Treatment Market

A detailed market share analysis in the Bleeding Disorders Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Bleeding Disorders Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Bleeding Disorders Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Bleeding Disorders Treatment Market

A strategic analysis of the Bleeding Disorders Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Bleeding Disorders Treatment Market, highlighting leading vendors and their innovative profiles. These include Alnylam Pharmaceuticals Inc., Amgen Inc., Baxter International Inc., Bayer AG, Biogen Inc., Bristol-Myers Squibb Company, CSL Behring, Emergent BioSolutions Inc., Grifols International, S.A., Kedrion S.p.A., Novo Nordisk A/S, Octapharma AG, Pfizer Inc., Sanofi S.A., and Xenetic Biosciences, Inc..

Market Segmentation & Coverage

This research report categorizes the Bleeding Disorders Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Disease Type, market is studied across Hemophilia A, Hemophilia B, and Von Willebrand Disease.
• Based on Drug Class, market is studied across Antibrinolytics, Desmopressin, Fibrin Sealant, Plasma Derived Coagulation Factor Concentrates, and Recombinant Coagulation Factor Concentrates.
• Based on Distribution Channel, market is studied across Compounding Pharmacies, Hospital Pharmacies, and Retail Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increase in the prevalence of liver disorders and anemia
    • 5.1.1.2. Rising healthcare expenditure by the government
    • 5.1.1.3. Considerable increase in healthcare accessibility in economies
  • 5.1.2. Restraints
    • 5.1.2.1. Lack of skilled professionals and trained expertise
  • 5.1.3. Opportunities
    • 5.1.3.1. Rising awareness regarding bleeding disorders
    • 5.1.3.2. Rise in demand due to lower infection risks and high investments in research and development
  • 5.1.4. Challenges
    • 5.1.4.1. High cost of medications of bleeding disorders treatment
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Bleeding Disorders Treatment Market, by Disease Type

• 6.1. Introduction
• 6.2. Hemophilia A
• 6.3. Hemophilia B
• 6.4. Von Willebrand Disease

7. Bleeding Disorders Treatment Market, by Drug Class

• 7.1. Introduction
• 7.2. Antibrinolytics
• 7.3. Desmopressin
• 7.4. Fibrin Sealant
• 7.5. Plasma Derived Coagulation Factor Concentrates
• 7.6. Recombinant Coagulation Factor Concentrates

8. Bleeding Disorders Treatment Market, by Distribution Channel

• 8.1. Introduction
• 8.2. Compounding Pharmacies
• 8.3. Hospital Pharmacies
• 8.4. Retail Pharmacies

9. Americas Bleeding Disorders Treatment Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Bleeding Disorders Treatment Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Bleeding Disorders Treatment Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Alnylam Pharmaceuticals Inc.
• 2. Amgen Inc.
• 3. Baxter International Inc.
• 4. Bayer AG
• 5. Biogen Inc.
• 6. Bristol-Myers Squibb Company
• 7. CSL Behring
• 8. Emergent BioSolutions Inc.
• 9. Grifols International, S.A.
• 10. Kedrion S.p.A.
• 11. Novo Nordisk A/S
• 12. Octapharma AG
• 13. Pfizer Inc.
• 14. Sanofi S.A.
• 15. Xenetic Biosciences, Inc.